Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.本發明揭示抗體-藥物結合物曲妥珠單抗-MCC-DM1與化療劑之組合，該抗體-藥物結合物曲妥珠單抗-MCC-DM1及該等化療劑包括其立體異構體、幾何異構體、互變異構體、溶劑合物、代謝物及醫藥學上可接受之鹽，該等組合適用於抑制腫瘤細胞生長且適用於治療諸如由HER2及KDR(VEGFR受體1)介導之癌症的病症。本發明揭示使用該等組合以供活體外、原位及活體內診斷，預防或治療哺乳動物細胞中之該等病症或相關病理病狀之方法。
